Coordination and administration of the Clinical Research Unit (KFO 329)
Thomas Benzing, Paul Brinkkötter
The Clinical Research Unit (CRU) 329 "Disease pathways in podocyte injury – from molecular mechanisms to individualized treatment options" is an interdisciplinary, cross-faculty research center of excellence funded through the Deutsche Forschungsgemeinschaft (DFG).
This CRU is based on the concept that minimal-change disease and focal-segmental glomerulosclerosis (FSGS) treatment requires a targeted approach that addresses the particular underlying pathogenic mechanism in each individual case. The overall aim of this CRU is to develop diagnostic tools and to characterize pathogenic pathways to allow individualized treatment approaches targeting the distinct pathomechanisms. Thus, we aim to convert FSGS management from a trial-and-error approach into a precision medicine strategy based on targeting individual disease mechanisms in patients.
The CRU 329, established in 2018, started in its second funding period in 2021 and is organized into 9 scientific and 3 central projects. The speaker of the CRU is Professor Thomas Benzing, director of the Department II of Internal Medicine (Divisions of Nephrology, Rheumatology, Diabetes and General Internal Medicine) of the University Hospital of Cologne. The scientific coordinator of the CRU is Professor Paul Brinkkoetter, Department II of Internal Medicine of the University Hospital of Cologne.
Fr Sa | 04. 05.02.2022
2. Kölner TMA Symposium
Sa · 26.03.2022
Nephrologie Aktuell 2022 Nephrologie trifft Rheumatologie
Do Sa | 29. 01.10.2022
31. Jahrestagung der Deutschen Transplantationsgesellschaft
Di Fr | 04. 07.10.2022
EMBO Workshop CILIA2022 5th European Cilia Meeting
Do So | 06. 09.10.2022
14. Jahrestagung der Deutschen Gesellschaft für Nephrologie